MELFALAN AMRING 50mg powder+solvent for injection / infusion solution medication leaflet

L01AA03 melphalan • Antineoplastic and immunomodulating agents | Alkylating agents | Nitrogen mustard analogues

Melphalan is a chemotherapy agent primarily used to treat certain types of cancer, such as multiple myeloma and ovarian cancer. It works by interfering with the DNA of cancer cells, preventing them from dividing and spreading.

Melphalan is administered either orally or intravenously, depending on the type and stage of cancer being treated. The treatment may be associated with side effects such as nausea, vomiting, decreased blood cell counts, and an increased risk of infections.

Patients undergoing melphalan treatment must be closely monitored by their doctor to assess effectiveness and manage any adverse reactions. It is important to strictly follow the prescribed doses.

This medication is used only under strict medical supervision and is not recommended for pregnant or breastfeeding women due to risks to the fetus or child.

General data about MELFALAN AMRING 50mg

Substance: melphalan

Date of last drug list: 01-01-2023

Commercial code: W66698001

Concentration: 50mg

Pharmaceutical form: powder+solvent for injection / infusion solution

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: DREHM PHARMA GMBH - AUSTRIA

Holder: AMRING FARMA SRL - ROMANIA

Number: 13114/2020/01

Shelf life: 2 years-after packing for marketing;after reconstituting the solution-it is used immediately

Concentrations available for melphalan

200mg, 2mg, 50mg